At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating gemcitabine hydrochloride, Selinexor, and 3 other interventions for Acinar Cell Adenocarcinoma of the Pancreas and 2 related conditions. Completed, enrolled 15 participants across 2 sites.
Detailed Summary
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Timeline
Interventions
Given IV
Given IV
Correlative studies
Correlative studies
Given IV